Open Biosystems, Inc., focused on the commercialization of leading-edge life science research tools for drug discovery, announced today that the Company has obtained an exclusive license to patented human-based trans-lentiviral gene expression technology owned by Tranzyme Pharma. Under the terms of the agreement, Open Biosystems gains exclusive rights to develop and commercialize products based on Tranzyme’s technology. In addition, the Company will assume Tranzyme’s operations located in Birmingham, Alabama, where Open Biosystems will continue to expand the development and production of lentiviral based products. In return, Tranzyme will receive minimum annual payments and royalties on sales of products and services resulting from the application of Tranzyme’s technology. Further financial details were not disclosed.
